NCT03473574View on ClinicalTrials.gov

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2022

Conditions
CholangiocarcinomaGall Bladder CarcinomaCholangiocarcinoma Non-resectableGallbladder Carcinoma Non-Resectable
Interventions
BIOLOGICAL

Durvalumab

immune checkpoint inhibitor

DRUG

Gemcitabine

standard chemotherapy

DRUG

Cisplatin

standard chemotherapy

BIOLOGICAL

Tremelimumab

immune checkpoint inhibitor

Trial Locations (1)

30625

Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hanover

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER